Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on progressing its strategy during the 2019 financial year including expectations for its full year results and progress of certain operational matters, including gaining United States Food and Drug Administration (“USFDA”) approval to begin commercial launch of TechnegasTM into the US in 2020.
For more information, download the attached PDF.
Download this document
